Pachychoroidale Erkrankungen

Zusammenfassung

Pachychoroidale Erkrankungen umfassen eine Gruppe von Erkrankungen, die charakteristische choroidale Merkmale zeigen. Diese können heutzutage durch multimodale Bildgebung immer differenzierter beschrieben werden und umfassen fokale oder diffuse Aderhautverdickungen mit erweiterten und hyperpermeablen choroidalen Gefäßen. Die richtige Diagnose und Abgrenzung von anderen exsudativen Erkrankungen ist für eine mögliche Therapie von großer Bedeutung.

Abstract

Pachychoroid spectrum disorders include uncomplicated pachychoroid, pachychoroid pigment epitheliopathy, central serous chorioretinopathy, pachychoroid neovasculopathy, polypoidal choroidal vasculopathy/aneurysmal type 1 neovascularisation, focal choroidal excavation and peripapillary pachychoroid syndrome. They are characterized by a thickened and hyperpermeable choroid and thinning of the choriocapillaris. The disorders are being diagnosed with increasing frequency and differentiation due to the advancement of multimodality imaging. Current understanding of the development, course, possible complications and treatment of these diseases is growing rapidly, but not all mechanisms have yet been elucidated. A correct diagnosis is important, especially the differentiation between the presence of active neovascularisation or a purely exudative stage, in order to initiate a therapy. It is also not yet clear why patients have a thickened choroid and why some of these patients develop pathological changes such as subretinal fluid, RPE changes or neovascularisation.

Kernaussagen

• Der Begriff „pachychoroid“ beschreibt zunächst lediglich das Vorliegen einer verdickten Choroidea und „Pachyvessel“ großlumige Gefäße der Haller-Schicht.

• Weitere Veränderungen sind großlumige Choroideagefäße mit gesteigerter Hyperpermeabilität sowie eine verdünnte Choriokapillaris.

• Bislang ließen sich die zugrunde liegenden Pathomechanismen für die Entstehung von pachychoroidalen Erkrankungen nicht abschließend klären.

• Für die Diagnosestellung sollte eine multimodale Bildgebung mittels FAG, ICGA und OCT (speziell SS-OCT oder SD-OCT mit EDI-Modus) durchgeführt werden. Die OCTA kann ergänzend weitere wichtige Befunde liefern.

• Es gibt bisher keine einheitliche Klassifizierung für die Erkrankungen des pachychoroidalen Spektrums.

• Für die Therapieentscheidung ist es sehr wichtig, zwischen einem rein exsudativen Befund oder dem Vorliegen einer exsudativen Neovaskularisation zu differenzieren.

Schlüsselwörter

Aderhaut - Anti-VEGF-Therapie - Chorioretinopathia centralis serosa

Key words

Pachychoroid - anti-VEGF therapy - central serous chorioretinopathy

Publication History

Article published online:
17 November 2022

• Literatur

• 1 Spraul CW, Lang GE, Grossniklaus HE. et al. Histologic and morphometric analysis of the choroid, Bruchʼs membrane, and retinal pigment epithelium in postmortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes. Surv Ophthalmol 1999; 44 (Suppl. 01) S10-S32 DOI: 10.1016/s0039-6257(99)00086-7.
• 2 Nickla DL, Wallman J. The multifunctional choroid. Prog Retin Eye Res 2010; 29: 144-168 DOI: 10.1016/j.preteyeres.2009.12.002.
• 3 Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina 2013; 33: 1659-1672 DOI: 10.1097/IAE.0b013e3182953df4.
• 4 Chen G, Tzekov R, Li W. et al. Subfoveal choroidal thickness in central serous chorioretinopathy: A meta-analysis. PLoS One 2017; 12: e0169152 DOI: 10.1371/journal.pone.0169152.
• 5 Cheung CMG, Lee WK, Koizumi H. et al. Pachychoroid disease. Eye (Lond) 2019; 33: 14-33 DOI: 10.1038/s41433-018-0158-4.
• 6 Castro-Navarro V, Behar-Cohen F, Chang W. et al. Pachychoroid: current concepts on clinical features and pathogenesis. Graefes Arch Clin Exp Ophthalmol 2021; 259: 1385-1400 DOI: 10.1007/s00417-020-04940-0.
• 7 Siedlecki J, Schworm B, Priglinger SG. The pachychoroid disease spectrum-and the need for a uniform classification system. Ophthalmol Retina 2019; 3: 1013-1015 DOI: 10.1016/j.oret.2019.08.002.
• 8 Spaide RF, Gemmy Cheung CM, Matsumoto H. et al. Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res 2022; 86: 100973 DOI: 10.1016/j.preteyeres.2021.100973.
• 9 Balaratnasingam C, Lee W-K, Koizumi H. et al. Polypoidal choroidal vasculopathy: A distinct disease or manifestation of many?. Retina 2016; 36: 1-8 DOI: 10.1097/IAE.0000000000000774.
• 10 Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina 2015; 35: 1-9 DOI: 10.1097/IAE.0000000000000331.
• 11 Zhao M, Célérier I, Bousquet E. et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 2012; 122: 2672-2679 DOI: 10.1172/JCI61427.
• 12 Brinks J, van Dijk EHC, Meijer OC. et al. Choroidal arteriovenous anastomoses: a hypothesis for the pathogenesis of central serous chorioretinopathy and other pachychoroid disease spectrum abnormalities. Acta Ophthalmol 2022; DOI: 10.1111/aos.15112.
• 13 Waldstein SM, Faatz H, Szimacsek M. et al. Comparison of penetration depth in choroidal imaging using swept source vs. spectral domain optical coherence tomography. Eye (Lond) 2015; 29: 409-415 DOI: 10.1038/eye.2014.319.
• 14 Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina 1994; 14: 231-242 DOI: 10.1097/00006982-199414030-00008.
• 15 Gal-Or O, Dansingani KK, Sebrow D. et al. Inner choroidal flow signal attenuation in pachychoroid disease: Optical coherence tomography angiography. Retina 2018; 38: 1984-1992 DOI: 10.1097/IAE.0000000000002051.
• 16 Forte R, Coscas F, Serra R. et al. Long-term follow-up of quiescent choroidal neovascularisation associated with age-related macular degeneration or pachychoroid disease. Br J Ophthalmol 2020; 104: 1057-1063 DOI: 10.1136/bjophthalmol-2019-315189.
• 17 Spaide RF, Campeas L, Haas A. et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996; 103: 2070-2079 DOI: 10.1016/s0161-6420(96)30386-2. discussion 2079–2080
• 18 Pauleikhoff L, Agostini H, Lange C. [Central serous chorioretinopathy]. Ophthalmologe 2021; 118: 967-980 DOI: 10.1007/s00347-021-01376-7.
• 19 Daruich A, Matet A, Marchionno L. et al. Acute central serous chorioretinopathy: Factors influencing episode duration. Retina 2017; 37: 1905-1915 DOI: 10.1097/IAE.0000000000001443.
• 20 Gilbert CM, Owens SL, Smith PD. et al. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 1984; 68: 815-820 DOI: 10.1136/bjo.68.11.815.
• 21 Kim JY, Park HS, Kim SY. Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2015; 253: 2129-2135 DOI: 10.1007/s00417-015-2965-7.
• 22 Izumi T, Koizumi H, Maruko I. et al. Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy. Br J Ophthalmol 2017; 101: 433-437 DOI: 10.1136/bjophthalmol-2016-308921.
• 23 Stellungnahme von BVA, DOG und RG zur Chorioretinopathia centralis serosa (CCS). springermedizin.de. Im Internet (Stand: 16.06.2022): https://www.springermedizin.de/stellungnahme-von-bva-dog-und-rg-zur-chorioretinopathia-centrali/19958220
• 24 Dansingani KK, Gal-Or O, Sadda SR. et al. Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of ‘expanded spectra’ – a review. Clin Exp Ophthalmol 2018; 46: 189-200 DOI: 10.1111/ceo.13114.
• 25 Lee WK, Iida T, Ogura Y. et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: A randomized clinical trial. JAMA Ophthalmol 2018; 136: 786-793 DOI: 10.1001/jamaophthalmol.2018.1804.
• 26 Chung H, Byeon SH, Freund KB. Focal choroidal excavation and its association with pachychoroid spectrum disorders: A review of the literature and multimodal imaging findings. Retina 2017; 37: 199-221 DOI: 10.1097/IAE.0000000000001345.
• 27 Phasukkijwatana N, Freund KB, Dolz-Marco R. et al. Peripapillary pachychoroid syndrome. Retina 2018; 38: 1652-1667 DOI: 10.1097/IAE.0000000000001907.